



October 31, 2024

Press Release

Eiken Chemical Co., Ltd.  
 Representative: Tsugunori Notomi,  
 President & CEO  
 Securities code: 4549 (TSE Prime Market)

**Notice On Differences between Financial Results Forecast and Financial Results  
 for the Semi-annual of Fiscal Year, ending March 31, 2025,  
 and Revision of Consolidated Financial Forecast**

The Company hereby announces differences between the consolidated financial results forecast for the semi-annual of the fiscal year ending March 31, 2025, announced on May 9, 2024, and the actual results for the same period announced today. In addition, in light of recent performance trends, the Company has also revised the full-year financial results forecast ending March 31, 2025, that it announced on May 9, 2024, as follows.

1. Differences between the consolidated financial results forecast and the actual financial results for the semi-annual of fiscal year (April 1, 2024 – September 30, 2024)

	Net sales	Operating income	Ordinary income	Profit attributable to owners of parent	Net income per share
Previous forecast (A)	Millions of yen 21,500	Millions of yen 2,870	Millions of yen 2,830	Millions of yen 2,230	Yen 64.45
Results (B)	19,729	1,566	1,698	1,309	37.84
Difference (B – A)	△1,770	△1,303	△1,131	△920	
Difference (%)	△8.2	△45.4	△40.0	△41.3	
(Reference) Results for the same period of fiscal 2024	20,264	2,148	2,225	1,618	43.69

Reasons for Differences Between Forecasts and Results

In the semi-annual of the fiscal year, sales of fecal immunochemical test reagents, our main product, did not increase as expected at the beginning of the fiscal year due to structural factors such as the holding back of purchases before bidding in overseas, inventory adjustments, demand for testing was lower than initial assumption due to the awareness of testing declined for genetic-related reagents amid the introduction of a fee for COVID-19 detection and the later market penetration of new products than assumption. As a result, each profit was lower than the previous forecast amid the change in the sales mix and the increase in the selling, general and administrative expenses.

2. Revision of the Consolidated Financial Forecast for the Full Fiscal Year Ending March 31, 2025 (April 1, 2024 to March 31, 2025)

	Net sales	Operating income	Ordinary income	Profit attributable to owners of parent	Net income per share
Previous forecast (A)	Millions of yen 43,100	Millions of yen 5,660	Millions of yen 5,620	Millions of yen 4,480	Yen 129.49
Revised forecast (B)	40,200	3,210	3,270	2,620	76.36
Difference (B - A)	△2,900	△2,450	△2,350	△1,860	
C h a n g e ( % )	△6.7	△43.3	△41.8	△41.5	
(Reference) Results for the fiscal year ended March 31, 2024	40,052	3,377	3,568	2,634	71.69

### Reasons for the Revision of the Consolidated Financial Forecast

Regarding the consolidated financial forecast, we have decided to revise it in consideration of the results of the semi-annual fiscal year amid an increase in development expenses due to compliance with regulations related to manufacturing approval applications, although we are working to promote sales, including new products, as the holding back before bidding in overseas until the semi-annual of the fiscal year has been resolved. However, we will continue to invest in R&D and human resources.

If we decide that it is necessary to revise the consolidated financial forecast in accordance with future performance trends, we will promptly announce it.

### 3. The forecast for dividends

There is no change to the forecast for dividends as the previous release.

Note: The forecasts listed above are based on information currently available to the Company and on certain assumptions deemed rational. Accordingly, the Company cannot make promises to achieve such forecasts. Actual results could significantly differ from the above forecasts due to a variety of factors